Zura Bio Limited (ZURA)Healthcare | Biotechnology | Henderson, United States | NasdaqCM
5.81 USD
+0.10
(1.751%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 5.82 +0.01 (0.172%) ⇧ (April 17, 2026, 6:24 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:11 a.m. EDT
Zura Bio is a high-risk speculative vehicle facing severe short-term resistance; while the $144M capital raise and positive trial narrative provide the underlying requisite for long-term recovery, the current fundamentals (negative earnings, high beta, no dividends) and bearish options flow suggest a 'buy the rumor, sell the news' risk is imminent. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.217815 |
| AutoETS | 0.217822 |
| MSTL | 0.222381 |
| AutoTheta | 0.226135 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.58 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.564 |
| Excess Kurtosis | -0.78 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 551,256,960 |
| Forward P/E | -58.10 |
| Beta | 0.24 |
| Website | https://zurabio.com |
As of April 19, 2026, 12:11 a.m. EDT: Options activity is dominated by Out-of-the-Money (OTM) puts, particularly at the $5.0 and $2.5 strikes, indicating significant defensive positioning and a bearish sentiment regarding downside risk. However, a notable cluster of OTM call Open Interest exists at the $7.5 strike, suggesting some speculation that a catalyst (likely Tibulizumab trial data) could push the price significantly higher. Implied Volatility is extremely low across most strikes, reflecting a lack of trades and low uncertainty in the short term, though this environment amplifies the impact of any single news event.
| Attribute | Value |
|---|---|
| 52 Week Change | 3.2408757 |
| Address1 | 1,489 W. Warm Springs Road |
| Address2 | Suite 110 |
| All Time High | 37.55 |
| All Time Low | 0.97 |
| Ask | 5.87 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 655,070 |
| Average Daily Volume3 Month | 632,011 |
| Average Volume | 632,011 |
| Average Volume10Days | 655,070 |
| Beta | 0.243 |
| Bid | 5.77 |
| Bid Size | 1 |
| Book Value | 1.378 |
| City | Henderson |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 5.81 |
| Current Ratio | 9.05 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 5.8299 |
| Day Low | 5.6401 |
| Display Name | Zura Bio |
| Earnings Timestamp | 1,773,950,400 |
| Earnings Timestamp End | 1,778,184,000 |
| Earnings Timestamp Start | 1,778,184,000 |
| Ebitda | -75,197,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -5.876 |
| Enterprise Value | 441,849,920 |
| Eps Current Year | -0.44 |
| Eps Forward | -0.1 |
| Eps Trailing Twelve Months | -1.06 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 6.1808 |
| Fifty Day Average Change | -0.37080002 |
| Fifty Day Average Change Percent | -0.05999224 |
| Fifty Two Week Change Percent | 324.0876 |
| Fifty Two Week High | 7.44 |
| Fifty Two Week High Change | -1.6300001 |
| Fifty Two Week High Change Percent | -0.21908604 |
| Fifty Two Week Low | 0.98 |
| Fifty Two Week Low Change | 4.83 |
| Fifty Two Week Low Change Percent | 4.928571 |
| Fifty Two Week Range | 0.98 - 7.44 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,679,405,400,000 |
| Float Shares | 52,743,238 |
| Forward Eps | -0.1 |
| Forward P E | -58.1 |
| Free Cashflow | -42,521,752 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 40 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.21123 |
| Held Percent Institutions | 0.56449 |
| Implied Shares Outstanding | 94,880,711 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,023-03-21 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development. It also develops Torudokimab (ZB-880), a fully human immunoglobulin G4 monoclonal antibody targeting interleukin-33 that has completed Phase 1 clinical studies; and Crebankitug (ZB-168), a fully human immunoglobulin G1 monoclonal antibody targeting interleukin-7 receptor alpha that has completed Phase 1 clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada. |
| Long Name | Zura Bio Limited |
| Market | us_market |
| Market Cap | 551,256,960 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1783060399 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -99,353,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 551,256,925 |
| Number Of Analyst Opinions | 6 |
| Open | 5.67 |
| Operating Cashflow | -64,815,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 702 825 9872 |
| Post Market Change | 0.010000229 |
| Post Market Change Percent | 0.17212097 |
| Post Market Price | 5.82 |
| Post Market Time | 1,776,464,693 |
| Previous Close | 5.71 |
| Price Eps Current Year | -13.204545 |
| Price Hint | 2 |
| Price To Book | 4.216255 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.816 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0999999 |
| Regular Market Change Percent | 1.75131 |
| Regular Market Day High | 5.8299 |
| Regular Market Day Low | 5.6401 |
| Regular Market Day Range | 5.6401 - 5.8299 |
| Regular Market Open | 5.67 |
| Regular Market Previous Close | 5.71 |
| Regular Market Price | 5.81 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 718,069 |
| Return On Assets | -0.32049 |
| Return On Equity | -0.52493 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 94,880,710 |
| Shares Percent Shares Out | 0.060599998 |
| Shares Short | 5,754,385 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 4,737,248 |
| Short Name | Zura Bio Limited |
| Short Percent Of Float | 0.0648 |
| Short Ratio | 10.3 |
| Source Interval | 15 |
| State | NV |
| Symbol | ZURA |
| Target High Price | 26.0 |
| Target Low Price | 11.0 |
| Target Mean Price | 15.5 |
| Target Median Price | 15.0 |
| Total Cash | 109,407,000 |
| Total Cash Per Share | 1.153 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.06 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 4.0246 |
| Two Hundred Day Average Change | 1.7853999 |
| Two Hundred Day Average Change Percent | 0.4436217 |
| Type Disp | Equity |
| Volume | 718,069 |
| Website | https://zurabio.com |
| Zip | 89,014 |